Effects of Aggressive Lipid Lowering Therapy With Atorvastatin on the Fibrous cap Thickness of Thin-cap Fibroatheroma: Three-Vessel Optical Coherence Tomography and Intravascular Ultrasound Study

Effects of Aggressive Lipid Lowering Therapy With Atorvastatin on the Fibrous cap Thickness of Thin-cap Fibroatheroma: Three-Vessel Optical Coherence Tomography and Intravascular Ultrasound Study - Effects of Aggressive Lipid Lowering Therapy With Atorvastatin on the Fibrous cap Thickness of Thin-cap Fibroatheroma: Three-Vessel Optical Coherence Tomography and Intravascular Ultrasound Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003620

Enrollment

Registered

2010-05-17

Start date

2008-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Interventions

10 to 20 mg pitavastatin daily started within 24 hours of PCI to maintain LDL-cho level less than 70mg/dl Control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with acute coronary syndrome (including ST-segment elevation acute myocardial infarction, non-ST-segment elevation myocardial infarction and unstable angina). 2. Patients who have at least one critical stenosis involving 75% or more of the stenosis 3. LDL-cho level between 100mg/dl and 180mg/dl 4. Patients providing written consent for participation in this clinical trial on their own volition after receiving a thorough explanation about the study

Exclusion criteria

Exclusion criteria: 1. Patients who will undergo elective percutaneous coronary intervention, 2. Patients who received thrombolytic therapy 3. Previous statin treatment 4. Severe left ventricular dysfunction (Ejection fraction <40% by echocardiogram), 5. Uncontrolled severe diabetes mellitus (HbA1c >12.0%).

Design outcomes

Primary

Measure	Time frame
For the plaques evaluated by OCT, what are the differences in plaque-stabilizing effects of atorvastatin in plaques with different characteristics (fibrous cap thickness)?	—

Secondary

Measure	Time frame
1. Are LDL-C and fibrous-cap thickness inversely-correlated? 2. Are plaque volume and fibrous-cap thickness inversely-correlated? 3. Does atorvastatin suppress new plaque formation?	—

Countries

Japan

Contacts

Public ContactKenichi Fujii

Hyogo College of Medicine Cardiovascular Division

kfujii@hyo-med.ac.jp0798-45-6553

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026